Medicus Pharma Ltd. Common Stock (MDCX) Research

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Market snapshot

Symbol
MDCX
Price
$0.46
Day change
+30.08%
Market cap
$10.1M
P/E ratio
-0.37x
52-week range
0.25-3.69
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome

    Medicus Pharma (NASDAQ:MDCX) said Monday it has submitted a Rare Pediatric Disease Designation request to the US Food and Drug Administration for SkinJect, its investigational microneedle patch for treating basal cell carcinoma in patients with Gorlin Syndrome. The submission follows an Orphan Drug Designation application and a registrational study design currently under FDA review for SkinJect, a dissolvable patch that delivers the chemotherapy drug doxorubicin directly into skin cancer lesions.

  • Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE

    Medicus Pharma (NASDAQ:MDCX) has submitted an Investigational New Drug application to Abu Dhabi's Department of Health for PRECISION-E2, a Phase 2a clinical trial evaluating its Teverelix drug candidate in women with symptomatic endometriosis in the United Arab Emirates. The study will enroll approximately 84 women across multiple sites in the UAE and test three different Teverelix dosing regimens, delivered by injection, to determine which dose and method best controls estrogen levels while minimizing side effects.

  • Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE

    Medicus Pharma (NASDAQ:MDCX) has submitted an Investigational New Drug application to Abu Dhabi's Department of Health for PRECISION-E2, a Phase 2a clinical...

Peer companies

  • Aligos Therapeutics, Inc. (ALGS)
  • Barinthus Biotherapeutics plc (BRNS)
  • Coeptis Therapeutics, Inc. (COEP)
  • Cue Biopharma, Inc. (CUE)
  • CEL-SCI Corporation (CVM)
  • INmune Bio, Inc. (INMB)
  • Century Therapeutics, Inc. (IPSC)
  • Karyopharm Therapeutics Inc. (KPTI)

Recent insider activity

  • Smith Andrew Alasdair — A-Award (200000 shares) on 2026-06-03
  • Rodgers Cathy McMorris — A-Award (50000 shares) on 2026-06-03
  • Raju Ajay — A-Award (50000 shares) on 2026-06-03
  • Mehmud Faisal — A-Award (250000 shares) on 2026-06-03
  • May Sara R. — A-Award (50000 shares) on 2026-06-03

Open Medicus Pharma Ltd. Common Stock (MDCX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.